Publications by authors named "David D Biggs"

Claim this Profile
A
A Multicenter Phase II Trial of Ipilimumab and Nivolumab in Unresectable or Metastatic Metaplastic Breast Cancer: Cohort 36 of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART, SWOG S1609).
Sylvia Adams, Megan Othus, Sandip Pravin Patel, Kathy D Miller, Rashmi Chugh, David D Biggs

Clin Cancer Res· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II study of carboplatin, pemetrexed, and bevacizumab in advanced nonsquamous non-small-cell lung cancer.
Nicole F Laslett, SuJung Park, Gregory A Masters, David D Biggs, Charles J Schneider

Cancer Med· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-Term Follow-Up of Cardiac Function and Quality of Life for Patients in NSABP Protocol B-31/NRG Oncology: A Randomized Trial Comparing the Safety and Efficacy of Doxorubicin and Cyclophosphamide (AC) Followed by Paclitaxel With AC Followed by Paclitaxel and Trastuzumab in Patients With Node-Positive Breast Cancer With Tumors Overexpressing Human Epidermal Growth Factor Receptor 2.
Patricia A Ganz, Edward H Romond, Reena S Cecchini, Priya Rastogi, Charles E Geyer, David D Biggs

J Clin Oncol· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Feasibility Assessment of Patient Reporting of Symptomatic Adverse Events in Multicenter Cancer Clinical Trials.
Ethan Basch, Amylou C Dueck, Lauren J Rogak, Lori M Minasian, William Kevin Kelly, David D Biggs

JAMA Oncol· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Definitive results of a phase III adjuvant trial comparing three chemotherapy regimens in women with operable, node-positive breast cancer: the NSABP B-38 trial.
Sandra M Swain, Gong Tang, Charles E Geyer, Priya Rastogi, James N Atkins, David D Biggs

J Clin Oncol· September 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer.
Edward H Romond, Jong-Hyeon Jeong, Priya Rastogi, Sandra M Swain, Charles E Geyer, David D Biggs

J Clin Oncol· November 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
BRCA1 E1644X: a deleterious mutation in an African American individual with early onset breast cancer.
S Eric Martin, Mark Sausen, Abraham Joseph, David D Biggs, Brewster F Kingham

Breast Cancer Res Treat· January 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase II study of estramustine, docetaxel, and exisulind in patients with hormone- refractory prostate cancer: results of cancer and leukemia group B trial 90004.
Nancy A Dawson, Susan Halabi, San-San Ou, David D Biggs, Anne Kessinger

Clin Genitourin Cancer· September 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
BRCA1 IVS2-2delA: a deleterious mutation in a family of Asian descent.
Eric S Martin, Carlo M Croce, David D Biggs, S Eric Martin

Cancer Genet Cytogenet· April 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A dose-escalation study of weekly topotecan, cisplatin, and gemcitabine front-line therapy in patients with inoperable non-small cell lung cancer.
Michael J Guarino, Charles J Schneider, Stephen S Grubbs, David D Biggs, Andrew L Himelstein

Oncologist· February 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis